DRUG · Unmapped registry intervention
NRM-823
Find medicine records ·
Find other trials using this name
Clinical trial
A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors
NCT07182149
Study summary
ClinicalTrials.govA Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors
Design: INTERVENTIONAL · Status: RECRUITING · Phase: PHASE1
Loading study purpose, treatment groups and outcomes…
View the complete registry record, eligibility and contacts at ClinicalTrials.gov
Drugs and interventions used in this trial
1 registeredThese interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.
No matching interventions in this trial.
Advertisement
Conditions
GEJ Adenocarcinomaunresolved
Ovarian Cancerverified · MONDO: ovarian cancer
NSCLCverified · MONDO: non-small cell lung carcinoma
Cervical Cancerverified · MONDO: cervical cancer
Endometrial Cancerverified · MONDO: endometrial cancer
Triple Negative Breast Cancer (TNBC)unresolved
Interventions
NRM-823DRUG
Sponsors & collaborators
Normunity AccelCo, Inc.lead sponsor
Mapped research locations
BostonMassachusetts, United States2PhiladelphiaPennsylvania, United States2HoustonTexas, United States1DallasTexas, United States1St LouisMissouri, United States1San AntonioTexas, United States1NashvilleTennessee, United States1Washington D.C.District of Columbia, United States1MinneapolisMinnesota, United States1DenverColorado, United States1Oklahoma CityOklahoma, United States1New HavenConnecticut, United States1
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT07182149 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.